Scilex Holding Company (SCLXW) stock declined over -7.83%, trading at $0.14 on NASDAQ, down from the previous close of $0.15. The stock opened at $0.17, fluctuating between $0.14 and $0.17 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 0.15 | 0.16 | 0.14 | 0.14 | 2.06K |
| Feb 04, 2026 | 0.17 | 0.18 | 0.15 | 0.15 | 8.71K |
| Feb 03, 2026 | 0.17 | 0.17 | 0.13 | 0.14 | 3.51K |
| Feb 02, 2026 | 0.14 | 0.15 | 0.13 | 0.15 | 25.81K |
| Jan 30, 2026 | 0.14 | 0.14 | 0.14 | 0.14 | 405 |
| Jan 29, 2026 | 0.11 | 0.13 | 0.11 | 0.11 | 3.52K |
| Jan 28, 2026 | 0.14 | 0.18 | 0.11 | 0.13 | 18.26K |
| Jan 26, 2026 | 0.11 | 0.14 | 0.11 | 0.14 | 5.91K |
| Jan 23, 2026 | 0.15 | 0.15 | 0.11 | 0.13 | 14.88K |
| Jan 22, 2026 | 0.12 | 0.16 | 0.12 | 0.15 | 11.87K |
| Jan 21, 2026 | 0.13 | 0.15 | 0.11 | 0.13 | 13.51K |
| Jan 20, 2026 | 0.15 | 0.15 | 0.15 | 0.15 | 50 |
| Jan 16, 2026 | 0.13 | 0.16 | 0.10 | 0.15 | 9.21K |
| Jan 15, 2026 | 0.18 | 0.18 | 0.18 | 0.18 | 5 |
| Jan 14, 2026 | 0.16 | 0.16 | 0.16 | 0.16 | 5 |
| Jan 13, 2026 | 0.16 | 0.16 | 0.16 | 0.16 | 9 |
| Jan 09, 2026 | 0.15 | 0.18 | 0.15 | 0.18 | 2.51K |
| Jan 08, 2026 | 0.17 | 0.17 | 0.17 | 0.17 | 5 |
| Jan 07, 2026 | 0.16 | 0.18 | 0.15 | 0.18 | 21.26K |
| Jan 06, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 7.2K |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Employees | 115 |
| Beta | 1.38 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep